CVS CVS Health Corporation Common Stock

NYSE · Health Care · Ver en SEC EDGAR ↗
$94,44
Precio · Ago 18, 2026
Fundamentales a fecha de Ago 5, 2026

Acerca de CVS Health Corporation Common Stock Descripción general de la empresa de Wikipedia

CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores.

Leer más

CVS Health Corporation is an American multinational healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands. The company is the world's second largest healthcare company, behind UnitedHealth Group. In 2023, the company was ranked 64th in the Forbes Global 2000. CVS started in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and their partner Ralph Hoagland. The name stood for Consumer Value Stores.

History

1960s

The first Consumer Value Store (CVS), selling health and beauty products, was founded in 1963, in Lowell, Massachusetts, by brothers Stanley and Sidney Goldstein and Ralph Hoagland. By 1964, CVS had 17 stores that sold primarily beauty products. In 1967, CVS opened its first stores with pharmacy departments in Warwick, Rhode Island, and Cumberland, Rhode Island. CVS was sold to Melville Corporation in 1969.

1970s

By 1970, CVS was operating 100 stores in New England and the Northeast. In 1972, CVS acquired 84 Clinton Drug and Discount Stores. This purchase introduced CVS to the Midwest with stores in Indiana. During 1977, CVS acquired 36 New Jersey–based Mack Drug stores.

1980s

In 1983, CVS began providing home health care for hemophilia. The company acquired Heartland Drug in 1988, a small pharmacy company in the Boston area giving it stores in the Boston metro including Watertown Square and Harvard Square.

1990s

CVS acquired 500 Peoples Drug stores in 1990, establishing the company in new mid-Atlantic markets including Washington, D.C., Pennsylvania, Maryland and Virginia. In 1994, it launched PharmaCare, a pharmacy benefit management (PBM) company. CVS became a standalone company trading on the New York Stock Exchange under the "CVS" ticker in 1996. Stanley Goldstein was the company's first chairman. CVS acquired over 2,500 Revco drug stores, establishing the company in additional Midwestern, Southeastern and Eastern states in 1997.

In 1998, the company acquired 207 stores from Arbor Drugs, giving CVS its first stores in Michigan. A year later, CVS acquired Soma.com, the first online pharmacy, and renamed it CVS.com to become the first fully integrated online and brick-and-mortar pharmacy offering to consumers.

2000s

In 2000, CVS acquired Stadtlander pharmacy from Bergen Brunswig Corporation, making CVS ProCare the largest specialty pharmacy in the U.S. at the time. In 2001, CVS launched the ExtraCare loyalty card program. Within a year, 30 million customers enrolled to earn rewards and receive discounts. CVS purchased 1,268 Eckerd drug stores and Eckerd Health Services, Eckerd's PBM/Mail-order pharmacy business, from JCPenney in 2004. The purchase expanded the company's footprint in Texas, Florida and other southern states.

2006 saw CVS acquiring 700 freestanding drug store operations of supermarket chain Albertsons, including stores trading under the Osco Drug and Sav-On Drugs banners. That same year, it acquired Minneapolis-based MinuteClinic. CVS Corporation and Caremark Rx, Inc. completed their transformative merger in 2007, creating CVS Caremark, an integrated pharmacy services provider, and the corporate headquarters remained in Woonsocket, RI. Tom Ryan, the chairman and CEO of CVS remained president and CEO of CVS Caremark Corporation, while Caremark's Edwin Crawford became the chairman of the board. CVS Caremark acquired 541 stores from Longs Drugs Stores Corp in California, Hawaii, and Nevada in 2008.

2010s

2011 saw Larry Merlo succeeding Tom Ryan as president and CEO of CVS Caremark. Merlo joined CVS/pharmacy in 1990, through the acquisition of Peoples Drug. On September 3, 2014, it was announced that CVS, as of midnight Tuesday September 2, 2014, would no longer sell tobacco products at all of its 7,700 locations nationwide, a month earlier than planned. It also announced it would change its corporate name to CVS Health to reflect "its broader health care commitment" and a desire to change the future health of Americans, although all retail stores would continue to be called "CVS/pharmacy", unless they did not contain a pharmacy, in which case they are just signed CVS. CVS Caremark acquired Coram in 2014, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group Inc. That same year, the company acquired 33 Miami-based Navarro Discount Pharmacy stores, the largest Hispanic-owned drugstore chain the United States. A year later in 2015, it acquired Omnicare, provider of pharmacy services to long-term care facilities. CVS Health acquired Target's 1,600+ pharmacies and retail medical clinics inside Target stores that same year. CVS has begun operating them through a store-within-a-store format.

CVS announced they would be installing 25 vending machines in high traffic areas like, bus terminals, airports, and college campuses in 2017. The first kiosks will be located in LaGuardia Airport and Boston's South Station Bus Terminal and will carry personal items such as toothpaste, deodorant, batteries, and healthy snack foods. In December, CVS announced they agreed to buy health insurer Aetna for about $207 per share, broken down into $145 in cash and the rest in stock, in December 2017. If approved, it would allow CVS to provide a broad range of health services to Aetna's 22 million medical members. On December 5, 2017, The Wall Street Journal reported that there was still a $69 billion deal pending between CVS and Aetna, so long as it received government approval. CVS CEO Larry Merlo had been named to run the combined company. In November 2018, CEO Larry Merlo told USA Today that the drugstore chain plans to renovate its stores to focus more on health care and less on retail following its merger with the health insurance company Aetna. The new strategy is to offer medical services along with prescription drugs, among other products. On June 4, 2019, USA Today reported on the planned expansion of a CVS Health store concept called HealthHUB to 1,500 locations by the end of 2021. The concept, launched in the Houston area in early 2019, realigns CVS retail outlets with a stronger focus on health care services. HealthHUB stores dedicate at least 20% of their floor space to health care services such as yoga classes and enlarged Minute Clinic spaces to offer more health assessments. To accommodate HealthHUB, CVS locations will reduce the floor space currently devoted to slower-selling merchandise, such as greeting cards. The store conversions to the HealthHUB format was paused in March 2020, due to the COVID-19 pandemic.

2020s

In February 2020, CVS announced changes to its board of directors, whose size was reduced from 16 to 13 directors. On November 18, 2021, the company announced that it plans to close 900 stores nationwide over the next three years because of what executives described as changes in consumer shopping behavior, population, and the future of health care needs. The closures would represent approximately 10 percent of stores in the US. On November 23, 2021, federal jury found that CVS, along with Walgreens and Walmart, "had substantially contributed to" the opioid crisis.

On December 2, 2021, CVS announced a strategic partnership with Microsoft to improve personalized care and digital health. In September 2022, CVS Health announced that it reached an agreement to buy at-home health company Signify Health for roughly $8 billion. It came one month after it announced a plan to move into primary care by the end of the year. On February 8, 2023, the company announced it has entered into a definitive agreement to acquire Oak Street Health in an all-cash transaction at $39 per share, representing an enterprise value of approximately $10.6 billion. The merger was completed in May 2023.

Finances

Subsidiaries and assets

Aetna

Aetna Inc. is an American managed health care company that sells traditional and consumer directed health care insurance and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans, primarily through employer-paid (fully or partly) insurance and benefit programs, and through Medicare.

CVS Pharmacy

CVS Pharmacy is one of the largest retail pharmacy chains in the United States, with 9,600 stores located in all 50 states, the District of Columbia, and Puerto Rico, operating primarily under the CVS Pharmacy, CVS, Longs Drugs, Navarro Discount Pharmacy and Drogaria Onofre names. CVS Pharmacy fills more than one of every five prescriptions in the United States, and 85% of U.S. population lives within 10 miles of a CVS Pharmacy. The ExtraCare loyalty program boasts over 70 million cardholders, making it the largest retail loyalty program in the country.

MinuteClinic

MinuteClinic retail medical clinics operate inside CVS Pharmacy locations within the United States. It is the largest walk-in medical clinic in the United States, with over 1,100 locations in 33 states and the District of Columbia. More than 50 percent of the U.S. population now lives within 10 miles of a MinuteClinic.

CVS Caremark

CVS Caremark provides comprehensive prescription benefit management services including mail order pharmacy services, specialty pharmacy and infusion services, plan design and administration, formulary management and claims processing. The company's clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans and other sponsors of health benefit plans and individuals throughout the United States. CVS Caremark manages the dispensing of prescription drugs for more than 75 million plan members through five mail order pharmacies, specialty pharmacies, long-term care pharmacies and national network of more than 68,000 retail pharmacies, consisting of approximately 41,000 chain pharmacies and 27,000 independent pharmacies.

CVS Media Exchange

CVS Media Exchange (CMX) is CVS Health's retail media network, launched in 2020.

CVS Specialty

CVS Specialty is the specialty pharmacy division that provides specialty pharmacy services for individuals with chronic or genetic diseases who require complex and expensive drug therapies. CVS Health operate 24 retail specialty pharmacy stores and 11 specialty mail order pharmacies, making them the largest specialty pharmacy in the United States.

Longs Drugs

Longs Drugs is a retail pharmacy chain with approximately 40 drug stores throughout the state of Hawaii. Prior to its acquisition by CVS in 2008, it was a chain of over 500 stores located primarily on the west coast of the United States. The stores in states other than Hawaii were rebranded to CVS.

Navarro Discount Pharmacies

Navarro Discount Pharmacies is a pharmacy chain, photo service, and pharmacy benefit manager in the United States. The company was acquired by CVS Health in September 2014, and is operated as a separate brand of CVS Health. The company mainly operates in Miami-Dade and Broward Counties and currently has 33 stores.

Accordant

Accordant provides rare disease case management and care management services for patients with rare, chronic diseases and their caregivers. Clients are primarily health plans, employers, and third party administrators (TPAs). The company is operated as a wholly owned subsidiary of CVS Health Corporation.

Coram

Coram is one of the nation's largest providers of infusion services, clinical and compliance monitoring and individual patient counseling and education. Coram cares for 140,000 patients annually through a national network of more than 85 locations as well as the largest home infusion network in the United States. The company was acquired by CVS Health in August 2015, and is operated as a wholly owned subsidiary of CVS Health Corporation.

Omnicare

Omnicare is a provider of pharmacy services to the long-term care market for patients in skilled nursing and assisted living facilities throughout North America. The company was acquired by CVS Health in August 2015, and is operated as a wholly owned subsidiary of CVS Health Corporation.

HealthHUB

HealthHUBs operate inside of select CVS Pharmacy locations and offer a variety of additional services in addition to traditional CVS locations. HealthHUB locations offer and expanded variety of Sleep Apnea, Durable Medical Equipment, Home and Health technology, and compression therapy. HealthHUBs are staffed by Care Concierges who are experts in HealthHub products and services. In addition, MinuteClinic locations that are HealthHub stores have expanded services and hire Medical Assistants, Registered Nurses, and Licensed Practical and Vocational Nurses to help support the Nurse Practitioners and Physician Assistants.

Store brands and private label brands

CVS Health offers a number of over-the-counter private label brands in their retail pharmacy stores, including grocery brands Gold Emblem™ and Gold Emblem Abound™; household products under the Total Home name; preservative-free vitamins and supplements under the Radiance PLATINUM line; and beauty and skin products through the Beauty 360, Nuance Salma Hayek, Makeup Academy, Skin+Pharmacy, Blade and Essence of Beauty lines.

Tobacco products removed from stores

On February 5, 2014, CVS announced that the company would discontinue the sale of all tobacco and cigarette products from their stores by October 1, 2014. In a statement explaining the change, CVS president and CEO Larry J. Merlo said, "We came to the decision that cigarettes and providing health care just don't go together in the same setting."

Criticism and controversy

Health and Medicare fraud

In the late 1980s and early 1990s, Caremark RX was involved in a number of health fraud and Medicare fraud scandals.

The combined price to settle this dispute with the U.S. Government cost the company over $250 million.

Elensys

In 1998, The Washington Post reported that CVS Corporation appeared to be sharing prescription drug information with the Woburn, Massachusetts, based marketing company, Elensys. According to the Post, Elensys received information on specific prescription drugs that individual CVS customers had purchased and used this information to send targeted direct mailings urging customers to renew prescriptions and promoting other products in which they might be interested. CVS and Elensys argued that there were no privacy issues because Elensys was acting solely as a contractor to CVS, and because the purpose of the mailings was to educate consumers. CVS claimed that it never shared customers' medical histories with Elensys (despite The Washington Post's indirect evidence that they had). George D. Lundberg, editor of the Journal of the American Medical Association, called the practice "a gross invasion" of privacy. Following a firestorm of criticism and complaints by consumers, CVS discontinued the relationship with Elensys, and moved the practice in-house.

Trio Drugs Lawsuit

On August 22, 2001, CVS Corp was sued for purchasing Trio Drugs' confidential records.

Boston prescriptions

During 2005, a series of prescription mistakes came to light in some of CVS Corporation's Boston-area stores. An investigation confirmed 62 errors or quality problems going back to 2002. In February 2006, the state Board of Pharmacy announced that the non-profit Institute for Safe Medication Practices (ISMP) would monitor all Massachusetts stores for the next two years.

Restatements

On November 15, 1999, CVS announced a restatement of its financial results for 1997, and 1998, following a Securities and Exchange Commission review of acquisition-related charges.

On February 25, 2005, CVS said it was reducing its previously announced fourth-quarter earnings by $40.5 million, to reflect the way it accounted for leased properties in its results.

Pharmaceutical kickbacks

In 2005, Caremark Rx paid $137.5 million to settle federal lawsuits filed by whistleblowers that accused a company it acquired in 2003, of improper dealings with pharmaceutical manufacturers.

The lawsuits said that the acquired company, AdvancePCS, accepted kickbacks from drug makers to promote their products over those of rivals under contracts with government programs including the Federal Employees Health Benefit Program, the Mail Handlers Health Benefit Program and Medicare health maintenance plans.

There was no admission of wrongdoing by Caremark or AdvancePCS.

CVS Caremark Corp. has changed their practices. The formulary revision process considers manufacturer rebates, payments from drug manufacturers for low placement on PBM (Pharmacy Benefit Manager) formularies, along with average wholesale price (AWP), drug availability, and bulk discounts when choosing at which co-pay a brand name drug should be placed.

Deceptive business practices

In February 2008, CVS settled a large civil lawsuit for deceptive business practices. The Kaiser Family Foundation reported:

CVS has agreed to a $38.5 million settlement in a multi-state civil deceptive-practices lawsuit against pharmacy benefit manager Caremark filed by 28 attorneys general, the Chicago Tribune reports. The attorneys general, led by Lisa Madigan (D) of Illinois and Douglas Ganslar (D) of Maryland, allege that Caremark "engaged in deceptive business practices" by informing physicians that patients or health plans could save money if patients were switched to certain brand-name prescription drugs (Miller, Chicago Tribune, 2/14).

However, the switch often saved patients and health plans only small amounts or increased their costs, while increasing Caremark's profits, Connecticut Attorney General Richard Blumenthal (D) said (Levick, Hartford Courant, 2/15). Pennsylvania Attorney General Tom Corbett (R) said the Pharmacy Benefit Manager (PBM), kept discounts and rebates that should have been passed on to employers and patients (Levy, AP/San Francisco Chronicle, 2/14). In addition, Caremark did not "adequately inform doctors" of the full financial effect of the switch and did not disclose that the switch would increase Caremark's profits, the lawsuit alleges (Chicago Tribune, 2/14).

...The settlement prohibits CVS from requesting prescription drug switches in certain cases, such as when the cost to the patient would be higher with the new prescription drug; when the original prescription drug's patent will expire within six months; and when patients were switched from a similar prescription drug within the previous two years (Hartford Courant, 2/15). Patients also have the ability to decline a switch from the prescribed treatment to the prescription offered by the pharmacy under the settlement, Madigan said (Bloomberg News/The Philadelphia Inquirer, 2/15).

Rhode Island Senate corruption case

In 2008, two former CVS executives, John R. "Jack" Kramer and Carlos Ortiz, were charged with 20 counts of mail fraud, bribery and conspiracy in relation to Operation Dollar Bill, a probe of corruption in the Rhode Island General Assembly. Kramer and Ortiz hired former state senator John Celona, who currently is serving 2+1⁄2 years on corruption charges involving CVS and other companies, as a media consultant for $12,000 a year. Celona was known for walking out on a pharmacy choice vote in the state senate while on the CVS payroll. Despite originally claiming CVS never bought any favors in his own trial, he testified against Kramer and Ortiz as the prosecution's star witness. On May 31, 2008, Kramer and Ortiz were acquitted on all counts. One juror went on the record as saying "My perception living in Rhode Island all my life is, 'Yeah, this probably did go on', but I didn't see any proof beyond a reasonable doubt that CVS did this."

FTC charges of privacy violations

On February 18, 2009, CVS Caremark agreed to settle Federal Trade Commission charges that it failed to take reasonable and appropriate security measures to protect the sensitive financial and medical information of its customers and employees, in violation of federal law. In a separate but related agreement, the company's pharmacy chain also has agreed to pay $2.25 million to resolve Department of Health and Human Services allegations that it violated the Health Insurance Portability and Accountability Act (HIPAA).

Business practices under investigation

On May 4, 2010, CVS Caremark Corp. announced that its business practices were being investigated by a group of 24 states, along with the District of Columbia and Los Angeles County. At issue is the post-merger relationship between CVS and Caremark. In addition, the company had earlier acknowledged in a filing with the Securities and Exchange Commission (SEC) that it had received a subpoena from the Office of Inspector General of the United States Department of Health and Human Services, requiring the company to provide information regarding the incentives the company provides to customers who transfer their prescriptions to CVS, including gift cards, goods and other incentives.

DEA investigation into oxycodone diversion

According to the U.S. Justice Department, in 2011, CVS pharmacies in Sanford, Florida, ordered enough painkillers to supply a population eight times its size. Sanford has a population of 53,000 but the supply would support 400,000. According to the Drug Enforcement Administration, in 2010, a single CVS pharmacy in Sanford ordered 1.8 million Oxycodone pills, an average of 137,994 pills a month. Other pharmacy customers in Florida averaged 5,364 oxycodone pills a month. DEA investigators serving a warrant to a CVS pharmacy in Sanford on October 18, 2011, noted that "approximately every third car that came through the drive-thru lane had prescriptions for oxycodone or hydrocodone". According to the DEA, a pharmacist at that location stated to investigators that "her customers often requested certain brands of oxycodone using street slang", an indicator that the drugs were being diverted and not used for legitimate pain management. In response, CVS in a statement issued February 17 in response to opioid trafficking questions from USA Today said the company is committed to working with the DEA and had taken "significant actions to ensure appropriate dispensing of painkillers in Florida".

FTC charges of deceptive pricing

On January 12, 2012, CVS Caremark paid $5 million to settle Federal Trade Commission charges that it misrepresented the prices of certain Medicare Part D prescription drugs – including drugs used to treat breast cancer symptoms and epilepsy – at CVS and Walgreens pharmacies.

Co-responsibility for opioid crisis

In September 2016, Massachusetts Attorney General Maura Healey announced a $795,000 settlement where CVS agrees to check a state database before filling the prescription for addictive opioids and other controlled substances. The settlement resolves previous allegations that the drugstore chain failed to provide pharmacists with access to the state of Massachusetts Prescription Monitoring Program (PMP). In July 2020, the attorney general of the Commonwealth of Kentucky filed a lawsuit against CVS alleging that their business practices aided in the advancing of the opioid epidemic.

In November 2021, a federal jury in Cleveland found that pharmacies operated by CVS Health, Walgreens, and Walmart were liable for contributing to the opioid epidemic in two Ohio counties. The trial lasted six weeks with the jury returning a verdict finding the Ohio pharmacies liable. It was the first trial where pharmacy companies defended themselves amidst the opioid epidemic.

In August 2022, the company was one of three chains ordered to pay damages of $650 million by a Cleveland judge in a lawsuit over opioid sales brought on by Lake County and Trumbull County in Ohio. The other two chains were Walgreens and Walmart, with two others, Rite Aid and Giant Eagle, settling before going to trial. Lawyers representing the counties claimed damages of $3.3 billion.

CFI lawsuit for consumer fraud

In July 2018, the Center for Inquiry filed a lawsuit against CVS for consumer fraud over its sale of homeopathic medicines. The filing in part contends that apart from being a waste of money, choosing homeopathic treatments to the exclusion of evidence-based medicines can result in worsened or prolonged symptoms, and in some cases, even death.

Abortion pill controversy

In January 2023, CVS announced their intentions to start dispensing mifepristone, one of the two drugs used in a medication abortion, following a change in regulations from the Food and Drug Administration. After receiving their certification to do so, CVS started offering abortion pills in jurisdictions where they are legal. The offering of abortion pills at pharmacies such as CVS has caused major political turmoil, and has resulted in numerous protests in-front of the pharmacies.

Pharmacists mistakenly cause an abortion

In October 2023, CVS mistakenly gave misoprostol, an abortion pill, to Tamika Thomas, a woman undergoing IVF who was supposed to be receiving a medication to help kick-start her pregnancy. In an interview with 8 News Now, Thomas stated she knew something was wrong when she experienced major cramping. "My cramping went beyond that. It was extreme. It was painful." As a result of the medication, Tamika lost both of her embryos. She stated, "They just killed my baby … Both my babies, because I transferred two embryos."

At the hearing, one of the pharmacists stated, "It's a human error. It was just a human error, and I'm so sorry." The two pharmacists were fined and placed on probation for one year. CVS Pharmacy was given a maximum fine of $10,000. The pharmacists will be able to return to work after one year if all conditions are met.

Animal welfare

In 2016, CVS committed to source 100% cage-free eggs by 2025, responding to pressure from animal welfare groups. In 2023, CVS announced that they reached this goal ahead of schedule, on December 31, 2022.

Community involvement and philanthropy

Since 1978, CVS Samaritan Vans have provided free roadside assistance to motorists and the community in numerous cities.

Played at the Rhode Island Country Club, the CVS Caremark Charity Classic was established to raise money for the support of non-profit agencies throughout New England. Since 1999, it has raised over $8 million for charity.

In 2024, CVS Health committed to invest nearly $35 million in equity to create two affordable housing developments in Hawai'i. A $17.5 million investment went toward the construction of 200 new affordable housing units at Kaiāulu o Kūku'ia (Lahaina, Maui), while another $17.3 million, along with The Kobayashi Group, The Ahe Group and CREA, LLC, was invested in the construction of 169 new affordable housing units at Parkway Village (Kapolei, Oahu).

Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗

Wikidata ↗

CVS Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas

Precio
$94.44
Capitalización Bursátil
$120.03B
P/E (TTM)
67.9
BPA (TTM)
$1.39
Ingresos (TTM)
$402.07B
Rendimiento div.
2.8%
ROE
2.4%
Deuda/Capital
0.0
Rango 52S
$70 – $111

CVS Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista

Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA

Ingresos y Beneficio Neto $402.07B
9-point trend, +117.6%
2017-12-31 2025-12-31
BPA $1.39
9-point trend, -78.4%
2017-12-31 2025-12-31
Flujo de caja libre $7.81B
9-point trend, +28.2%
2017-12-31 2025-12-31
Márgenes 0.44%
2017-12-31 2017-12-31

Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?

Métrica
Tendencia a 5 años
CVS
Mediana de Pares
P/E (TTM)
5-point trend, +233.2%
67.9
42.6
P/S (TTM) (P/V (TTM))
5-point trend, -46.3%
0.3
0.3
P/B (P/C)
5-point trend, -26.2%
1.6
0.9
EV / EBITDA
5-point trend, -56.7%
11.8
Price / FCF (Precio / FCF)
5-point trend, +49.2%
15.4

Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC

Métrica
Tendencia a 5 años
CVS
Mediana de Pares
Operating Margin (Margen Operativo)
5-point trend, -74.3%
1.2%
Net Profit Margin (Margen de Beneficio Neto)
5-point trend, -83.8%
0.44%
-7.0%
ROA
5-point trend, -79.5%
0.70%
-10.6%
ROE
5-point trend, -78.5%
2.4%
-20.8%
ROIC
5-point trend, -62.4%
5.0%

Salud financiera Deuda, liquidez, solvencia — solidez del balance general

Métrica
Tendencia a 5 años
CVS
Mediana de Pares
Debt / Equity (Deuda / Patrimonio)
5-point trend, -100.0%
0.0
8.0
Current Ratio (Ratio corriente)
5-point trend, -4.8%
0.8
1.1
Quick Ratio (Ratio Rápido)
5-point trend, +4.2%
0.6

Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años

Métrica
Tendencia a 5 años
CVS
Mediana de Pares
Revenue YoY (Ingresos interanuales)
5-point trend, +37.6%
7.8%
Revenue CAGR 3Y (Ingresos CAGR 3A)
5-point trend, +37.6%
7.6%
Revenue CAGR 5Y (Ingresos CAGR 5A)
5-point trend, +37.6%
8.4%
EPS YoY (EPS interanual)
5-point trend, -76.9%
-62.0%
Net Income YoY (Beneficio Neto interanual)
5-point trend, -77.9%
-61.7%

Métricas por acción BPA, valor contable por acción, flujo de caja por acción, dividendo por acción

Métrica
Tendencia a 5 años
CVS
Mediana de Pares
EPS (Diluted) (BPA (Diluido))
5-point trend, -76.9%
$1.39

Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar

Métrica
Tendencia a 5 años
CVS
Mediana de Pares
Payout Ratio (Ratio de Pago)
5-point trend, +478.9%
192.1%

Dividendos Rendimiento, ratio de pago, historial de dividendos, CAGR a 5 años

Rendimiento por Dividendo
2.8%
Ratio de Pago
192.1%
CAGR de Dividendos a 5 años
Fecha ex-dividendoMonto
23 de julio de 2026$0,6650
23 de abril de 2026$0,6650
22 de enero de 2026$0,6650
23 de octubre de 2025$0,6650
22 de julio de 2025$0,6650
22 de abril de 2025$0,6650
23 de enero de 2025$0,6650
21 de octubre de 2024$0,6650
22 de julio de 2024$0,6650
19 de abril de 2024$0,6650
19 de enero de 2024$0,6650
19 de octubre de 2023$0,6050
20 de julio de 2023$0,6050
20 de abril de 2023$0,6050
19 de enero de 2023$0,6050
20 de octubre de 2022$0,5500
21 de julio de 2022$0,5500
21 de abril de 2022$0,5500
20 de enero de 2022$0,5500
21 de octubre de 2021$0,5000

CVS Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista

COMPRA 33 analistas
  • Compra fuerte 8 24,2%
  • Compra 20 60,6%
  • Mantener 5 15,2%
  • Venta 0 0,0%
  • Venta fuerte 0 0,0%

Precio objetivo a 12 meses

25 analistas · 2026-08-17
Objetivo mediano $116.00 +22,8%
Objetivo medio $116.08 +22,9%

Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados

Sorpresa Media
0.37%
Período EPS Actual EPS est. Sorpresa
30 de junio de 2026 $2.58 $1.87 0.71%
31 de marzo de 2026 $2.57 $2.22 0.35%
31 de diciembre de 2025 $1.09 $1.00 0.09%
30 de septiembre de 2025 $1.60 $1.38 0.22%
30 de junio de 2025 $1.81 $1.47 0.34%
31 de marzo de 2025 $2.25 $1.72 0.53%

Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector

Ticker Capitalización Bursátil P/E Ingresos interanuales Margen Neto ROE Margen Bruto
CVS $100.87B 57.1 7.8% 0.44% 2.4%
CI $72.51B 12.4 11.2% 2.2% 14.4%
DGX $19.09B 19.8 11.8% 9.0% 14.2%
LH $20.62B 24.0 7.2% 6.3% 10.3% 28.8%
GH $13.34B -30.8 32.9% -42.4% 205.7%
LH $20.62B 24.0 7.2% 6.3% 10.3% 28.8%
BTSG $7.20B 43.0 28.2% 1.5% 10.8% 11.8%
DVA $7.79B 11.5 6.5% 5.5% -281.8%
HNGE $0 -6.0 50.6% -89.9% -299.8% 79.7%
CHE 23.3 4.1% 10.5% 24.4%
HIMS 63.7 59.0% 5.5% 23.3% 73.8%

Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja

Estado de resultados 16
Datos anuales de Estado de resultados para CVS
Métrica Tendencia 20252024202320222021202020192018201720162015
Revenue 10-point trend, +162.3% $402.07B $372.81B $357.78B $322.47B $292.11B $268.71B $256.78B · $184.79B $177.55B $153.29B
Cost of Revenue 10-point trend, +74.5% $221.17B $206.29B $217.10B $196.89B $175.80B $163.98B $158.72B · $153.45B $146.53B $126.76B
Gross Profit 3-point trend, +7.6% · · · · · · · · $28.55B $28.86B $26.53B
Operating Expenses 10-point trend, +2230.4% $397.41B $364.29B $344.03B $314.51B $278.80B $254.79B $244.79B · $18.81B $18.45B $17.05B
Operating Income 10-point trend, -50.8% $4.66B $8.52B $13.74B $7.95B $13.31B $13.91B $11.99B · $9.54B $10.39B $9.47B
Interest Expense 8-point trend, +209.4% · · $2.66B $2.29B $2.50B $2.91B $3.04B · $1.06B $1.08B $859M
Interest Income 3-point trend, +0.0% · · · · · · · · $21M $20M $21M
Other Non-op 9-point trend, +500.0% $112M $99M $88M $169M $182M $206M $124M · $-208M $-28M ·
Pretax Income 10-point trend, -75.2% $2.14B $6.15B $11.17B $5.84B $10.54B $9.77B $9.00B · $8.27B $8.64B $8.62B
Income Tax 10-point trend, -88.0% $408M $1.56B $2.81B $1.51B $2.55B $2.57B $2.37B · $1.64B $3.32B $3.39B
Net Income 10-point trend, -66.2% $1.77B $4.61B $8.34B $4.31B $8.00B $7.18B $6.63B · $6.62B $5.32B $5.24B
EPS (Basic) 10-point trend, -70.0% $1.40 $3.67 $6.49 $3.29 $6.07 $5.48 $5.10 · $6.47 $4.93 $4.66
EPS (Diluted) 10-point trend, -70.0% $1.39 $3.66 $6.47 $3.26 $6.02 $5.46 $5.08 · $6.44 $4.90 $4.63
Shares (Basic) 10-point trend, +13.3% 1,267,000,000 1,259,000,000 1,285,000,000 1,312,000,000 1,319,000,000 1,309,000,000 1,301,000,000 · 1,020,000,000 1,073,000,000 1,118,000,000
Shares (Diluted) 10-point trend, +12.9% 1,271,000,000 1,262,000,000 1,290,000,000 1,323,000,000 1,329,000,000 1,314,000,000 1,305,000,000 · 1,024,000,000 1,079,000,000 1,126,000,000
EBITDA 10-point trend, -2.0% $9.27B $13.11B $18.11B $11.99B $17.70B $18.35B $16.36B · $12.00B $10.34B $9.45B
Balance general 31
Datos anuales de Balance general para CVS
Métrica Tendencia 20252024202320222021202020192018201720162015
Cash & Equivalents 10-point trend, +243.8% $8.45B $8.59B $8.20B $12.95B $9.41B $7.85B $5.68B · $1.70B $3.37B $2.46B
Short-term Investments 10-point trend, +2337.5% $2.15B $2.41B $3.26B $2.78B $3.12B $3.00B $2.37B · $111M $87M $88M
Receivables 10-point trend, +234.6% $39.78B $36.47B $35.23B $27.28B $24.43B $21.74B $19.62B · $13.18B $12.16B $11.89B
Inventory 10-point trend, +37.5% $19.25B $18.11B $18.02B $19.09B $17.76B $18.50B $17.52B · $15.30B $14.76B $14.00B
Other Current Assets 11-point trend, +605.1% $5.09B $3.08B $3.15B $2.64B $5.29B $5.28B $5.11B $4.53B $945M $660M $722M
Current Assets 11-point trend, +156.2% $74.71B $68.64B $67.86B $65.63B $60.01B $56.37B $50.30B $45.20B $31.23B $31.04B $29.16B
PP&E (Net) 8-point trend, +30.6% · · · $12.87B $12.90B $12.61B $12.04B $11.36B $10.29B $10.18B $9.86B
PP&E (Gross) 7-point trend, +64.5% · · · $34.60B $33.55B $31.31B $28.93B · $24.29B $22.80B $21.04B
Accum. Depreciation 7-point trend, +92.1% · · · $21.48B $20.65B $18.70B $16.89B · $14.00B $12.63B $11.18B
Goodwill 10-point trend, +124.3% $85.48B $91.27B $91.27B $78.15B $79.12B $79.55B $79.75B · $38.45B $38.25B $38.11B
Intangibles 11-point trend, +83.8% $25.51B $27.32B $29.23B $24.80B $29.03B $31.14B $33.12B $36.31B $13.63B $13.51B $13.88B
Other Non-current Assets 11-point trend, +394.0% $7.11B $4.79B $4.66B $4.62B $4.71B $4.62B $4.60B $4.53B $1.42B $1.49B $1.44B
Total Assets 11-point trend, +174.3% $253.54B $253.22B $249.73B $228.28B $233.00B $230.72B $222.45B $216.67B $95.13B $94.46B $92.44B
Accounts Payable 3-point trend, +18.3% · · · · · · · · $8.86B $7.95B $7.49B
Accrued Liabilities 11-point trend, +227.8% $22.39B $20.81B $23.52B $18.75B $17.67B $14.24B $12.13B $10.66B $6.58B $6.94B $6.83B
Short-term Debt 9-point trend, +0.00 $0 $2.12B $200M $0 · $0 $0 · $1.28B $1.87B $0
Current Liabilities 11-point trend, +282.8% $88.69B $84.61B $79.19B $69.42B $67.81B $62.02B $53.30B $45.76B $30.65B $26.25B $23.17B
Capital Leases 9-point trend, +4358.5% $13.64B $14.90B $16.03B $16.80B $18.18B $18.76B $18.93B $18.83B $306M · ·
Deferred Tax 11-point trend, -9.1% $3.83B $3.81B $4.31B $4.02B $6.27B $6.79B $7.29B $7.74B $3.00B $4.21B $4.22B
Other Non-current Liabilities 11-point trend, +339.1% $6.77B $5.43B $6.21B $6.73B $1.90B $2.35B $2.16B $2.26B $1.28B $1.55B $1.54B
Total Liabilities 9-point trend, +210.2% $178.16B $177.49B $173.09B $156.51B $157.62B $161.01B $158.28B $157.95B $57.44B · ·
Long-term Debt 5-point trend, +149.0% · · · · · · $68.48B $72.61B $27.00B $25.70B $27.50B
Total Debt 7-point trend, -100.0% $0 $2.12B $200M · · · $3.78B · $27.00B $27.53B $27.46B
Common Stock 9-point trend, +5.9% · $18M $18M $18M $17M $17M $17M · $17M $17M $17M
Paid-in Capital 3-point trend, +3.7% · · · · · · · · $32.08B $31.62B $30.95B
Retained Earnings 11-point trend, +72.4% $61.20B $62.84B $61.60B $56.40B $54.91B $49.64B $45.11B $41.09B $43.56B $38.98B $35.51B
Treasury Stock 10-point trend, +27.4% $36.79B $36.82B $33.84B $31.86B $28.17B $28.18B $28.23B · $37.80B $33.45B $28.89B
AOCI 10-point trend, +213.4% $406M $-120M $-297M $-1.26B $965M $1.41B $1.02B · $-165M $-305M $-358M
Stockholders' Equity 11-point trend, +102.2% $75.21B $75.56B $76.46B $71.47B $75.08B $69.39B $63.86B $58.40B $37.69B $36.83B $37.20B
Liabilities + Equity 10-point trend, +174.3% $253.54B $253.22B $249.73B $228.28B $233.00B $230.72B $222.45B · $95.13B $94.46B $92.44B
Shares Outstanding 10-point trend, +15.4% 1,271,000,000 1,260,000,000 1,288,000,000 1,300,000,000 1,322,000,000 1,310,000,000 1,302,000,000 · 1,712,000,000 1,061,000,000 1,101,000,000
Flujo de Efectivo 19
Datos anuales de Flujo de Efectivo para CVS
Métrica Tendencia 20252024202320222021202020192018201720162015
D&A 10-point trend, +120.2% $4.61B $4.60B $4.37B $4.22B $4.49B $4.44B $4.37B · $2.48B $2.48B $2.09B
Stock-based Comp 10-point trend, +132.6% $535M $540M $588M $447M $484M $400M $453M · $234M $222M $230M
Deferred Tax 10-point trend, +143.6% $102M $-572M $-676M $-2.03B $-402M $-564M $-649M · $-1.42B $3M $-234M
Amort. of Intangibles 10-point trend, +227.3% $2.00B $2.00B $1.90B $1.80B $2.20B $2.30B $2.40B · $817M $795M $611M
Restructuring · · · · · · · · $215M · ·
Other Non-cash 8-point trend, +3801.1% $3.63B $-72M $804M $9.41B $5.79B $4.41B $2.04B · $93M · ·
Operating Cash Flow 10-point trend, +24.6% $10.64B $9.11B $13.43B $16.18B $18.27B $15.87B $12.85B · $8.01B $10.14B $8.54B
CapEx 10-point trend, +19.6% $2.83B $2.78B $3.03B $2.73B $2.52B $2.44B $2.46B · $1.92B $2.22B $2.37B
Investing Cash Flow 10-point trend, +56.3% $-5.87B $-7.61B $-20.89B $-5.05B $-5.26B $-5.53B $-3.34B · $-2.88B $-2.47B $-13.42B
Debt Issued 10-point trend, -73.2% $3.97B $7.91B $10.90B $0 $987M $9.96B $3.74B · $0 $3.46B $14.80B
Net Debt Issued 9-point trend, -97.1% $340M $3.14B $7.73B $-4.21B $-9.27B $-5.67B $-4.60B · · $-2.49B $11.90B
Stock Repurchased 10-point trend, -100.0% $0 $3.02B $2.01B $3.50B $0 $0 $0 · $4.36B $4.46B $5.00B
Net Stock Activity 8-point trend, +100.0% $0 $-3.02B $-2.01B $-3.50B · · $0 · $-4.36B $-4.46B $-5.00B
Dividends Paid 10-point trend, +115.5% $3.40B $3.37B $3.13B $2.91B $2.62B $2.62B $2.60B · $2.05B $1.84B $1.58B
Financing Cash Flow 10-point trend, -201.3% $-4.94B $-1.14B $2.68B $-10.52B $-11.36B $-7.70B $-7.65B · $-6.75B $-6.76B $4.88B
Net Change in Cash 10-point trend, -681.8% $-172M $359M $-4.78B $614M $1.65B $2.63B $1.85B · $-1.62B $912M $-22M
Taxes Paid 10-point trend, -33.8% $2.17B $1.70B $3.52B $4.12B $3.19B $2.93B $2.72B · $2.91B $3.06B $3.27B
Free Cash Flow 10-point trend, +29.1% $7.81B $6.33B $10.39B $13.45B $15.74B $13.43B $10.39B · $6.09B $7.84B $6.04B
Levered FCF 8-point trend, +52.2% · · $8.40B $11.76B $13.85B $11.29B $8.15B · $5.24B $7.18B $5.52B
Rentabilidad 8
Datos anuales de Rentabilidad para CVS
Métrica Tendencia 20252024202320222021202020192018201720162015
Gross Margin 3-point trend, -10.7% · · · · · · · · 15.4% 16.3% 17.3%
Operating Margin 10-point trend, -81.2% 1.2% 2.3% 3.8% 2.4% 4.5% 5.2% 4.7% · 5.1% 5.8% 6.2%
Net Margin 10-point trend, -87.1% 0.44% 1.2% 2.3% 1.3% 2.7% 2.7% 2.6% · 3.6% 3.0% 3.4%
Pretax Margin 10-point trend, -90.6% 0.53% 1.7% 3.1% 1.8% 3.6% 3.6% 3.5% · 4.5% 4.9% 5.6%
EBITDA Margin 10-point trend, -62.7% 2.3% 3.5% 5.1% 3.7% 6.1% 6.8% 6.4% · 6.5% 5.8% 6.2%
ROA 10-point trend, -88.8% 0.70% 1.8% 3.5% 1.8% 3.4% 3.2% 3.0% · 7.0% 5.7% 6.2%
ROE 10-point trend, -83.1% 2.4% 6.1% 11.3% 5.7% 10.9% 10.8% 10.8% · 17.8% 14.4% 13.9%
ROIC 10-point trend, -43.6% 5.0% 8.2% 13.4% 8.1% 13.3% 14.8% 13.1% · 11.8% 9.9% 8.9%
Liquidez y Solvencia 5
Datos anuales de Liquidez y Solvencia para CVS
Métrica Tendencia 20252024202320222021202020192018201720162015
Current Ratio 10-point trend, -35.7% 0.8 0.8 0.9 0.9 0.9 0.9 0.9 · 1.0 1.2 1.3
Quick Ratio 10-point trend, -8.8% 0.6 0.6 0.6 0.6 0.5 0.5 0.5 · 0.5 0.6 0.6
Debt / Equity 7-point trend, -100.0% 0.0 0.0 0.0 · · · 0.1 · 0.7 0.7 0.7
LT Debt / Equity 3-point trend, -16.7% · · · · · · · · 0.6 0.7 0.7
Interest Coverage 8-point trend, -53.0% · · 5.2 3.4 5.3 4.8 3.9 · 9.0 9.6 11.0
Eficiencia 3
Datos anuales de Eficiencia para CVS
Métrica Tendencia 20252024202320222021202020192018201720162015
Asset Turnover 10-point trend, -13.1% 1.6 1.5 1.5 1.4 1.3 1.2 1.2 · 1.9 1.9 1.8
Inventory Turnover 10-point trend, +21.1% 11.8 11.4 11.7 10.7 9.7 9.1 9.3 · 10.4 10.3 9.8
Receivables Turnover 10-point trend, -25.8% 10.5 10.4 11.4 12.5 12.7 13.0 13.8 · 14.6 14.8 14.2
Por Acción 7
Datos anuales de Por Acción para CVS
Métrica Tendencia 20252024202320222021202020192018201720162015
Book Value / Share 10-point trend, +75.2% $59.18 $59.97 $59.36 $54.63 $56.79 $52.97 $49.05 · $37.17 $34.71 $33.78
Revenue / Share 10-point trend, +132.4% $316.34 $295.41 $277.35 $243.74 $219.80 $204.49 $196.76 · $180.43 $164.53 $136.14
Cash Flow / Share 10-point trend, +12.0% $8.37 $7.22 $10.41 $12.23 $13.74 $12.07 $9.85 · $7.82 $9.33 $7.47
Cash / Share 10-point trend, +197.8% $6.65 $6.81 $6.36 $9.96 $7.12 $6.00 $4.36 · $1.67 $3.18 $2.23
Dividend / Share 10-point trend, +90.0% $3 $3 $2 $2 $2 $2 $2 · $2 $2 $1
Dividend Paid / Share · · · · · · · · $2 · ·
EPS (TTM) 10-point trend, -70.0% $1.39 $3.66 $6.47 $3.26 $6.02 $5.46 $5.08 · $6.44 $4.90 $4.63
Tasas de Crecimiento 10
Datos anuales de Tasas de Crecimiento para CVS
Métrica Tendencia 20252024202320222021202020192018201720162015
Revenue YoY 5-point trend, -9.9% 7.8% 4.2% 10.9% 10.4% 8.7% · · · · · ·
Revenue CAGR 3Y 3-point trend, -23.8% 7.6% 8.5% 10.0% · · · · · · · ·
Revenue CAGR 5Y 8.4% · · · · · · · · · ·
EPS YoY 5-point trend, -704.5% -62.0% -43.4% 98.5% -45.9% 10.3% · · · · · ·
EPS CAGR 3Y 3-point trend, -524.9% -24.7% -15.3% 5.8% · · · · · · · ·
EPS CAGR 5Y -23.9% · · · · · · · · · ·
Net Income YoY 5-point trend, -638.7% -61.7% -44.7% 93.5% -46.1% 11.5% · · · · · ·
Net Income CAGR 3Y 3-point trend, -600.0% -25.7% -16.8% 5.1% · · · · · · · ·
Net Income CAGR 5Y -24.4% · · · · · · · · · ·
Dividend CAGR 5Y 5.3% · · · · · · · · · ·
Valoración (TTM) 16
Datos anuales de Valoración (TTM) para CVS
Métrica Tendencia 20252024202320222021202020192018201720162015
Revenue TTM 10-point trend, +162.3% $402.07B $372.81B $357.78B $322.47B $292.11B $268.71B $256.78B · $184.79B $177.55B $153.29B
Net Income TTM 10-point trend, -66.2% $1.77B $4.61B $8.34B $4.31B $8.00B $7.18B $6.63B · $6.62B $5.32B $5.24B
Market Cap 10-point trend, -6.3% $100.87B $56.56B $101.70B $121.15B $136.38B $89.47B $96.73B · $73.52B $83.72B $107.64B
Enterprise Value 7-point trend, -31.9% $90.27B $47.69B $90.45B · · · $92.45B · $98.71B $107.80B $132.56B
P/E 10-point trend, +170.4% 57.1 12.3 12.2 28.6 17.1 12.5 14.6 · 11.3 16.1 21.1
P/S 10-point trend, -64.3% 0.3 0.2 0.3 0.4 0.5 0.3 0.4 · 0.4 0.5 0.7
P/B 10-point trend, -53.7% 1.3 0.7 1.3 1.7 1.8 1.3 1.5 · 2.0 2.3 2.9
P / Cash Flow 10-point trend, -25.9% 9.5 6.2 7.6 7.5 7.5 5.6 7.5 · 9.2 8.3 12.8
P / FCF 10-point trend, -27.4% 12.9 8.9 9.8 9.0 8.7 6.7 9.3 · 12.1 10.7 17.8
EV / EBITDA 7-point trend, -30.5% 9.7 3.6 5.0 · · · 5.7 · 8.2 10.4 14.0
EV / FCF 7-point trend, -47.3% 11.6 7.5 8.7 · · · 8.9 · 16.2 13.7 21.9
EV / Revenue 7-point trend, -74.0% 0.2 0.1 0.3 · · · 0.4 · 0.5 0.6 0.9
Dividend Yield 10-point trend, +130.8% 3.4% 6.0% 3.1% 2.4% 1.9% 2.9% 2.7% · 2.8% 2.2% 1.5%
Earnings Yield 10-point trend, -63.1% 1.8% 8.2% 8.2% 3.5% 5.8% 8.0% 6.8% · 8.9% 6.2% 4.7%
Payout Ratio 10-point trend, +538.8% 192.1% 73.1% 37.5% 70.1% 33.2% 36.5% 39.2% · 30.9% 34.6% 30.1%
Annual Payout 10-point trend, +115.5% $3.40B $3.37B $3.13B $2.91B $2.62B $2.62B $2.60B · $2.05B $1.84B $1.58B

Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años

Estado de resultados
2025-12-312024-12-312023-12-312022-12-312021-12-31
Ingresos $402.07B$372.81B$357.78B$322.47B$292.11B
Margen Operativo % 1.2%2.3%3.8%2.4%4.5%
Beneficio neto $1.77B$4.61B$8.34B$4.31B$8.00B
EPS Diluido $1.39$3.66$6.47$3.26$6.02
Balance general
2025-12-312024-12-312023-12-312022-12-312021-12-31
Deuda / Patrimonio 0.00.00.0
Ratio corriente 0.80.80.90.90.9
Ratio Rápido 0.60.60.60.60.5
Flujo de Efectivo
2025-12-312024-12-312023-12-312022-12-312021-12-31
Flujo de caja libre $7.81B$6.33B$10.39B$13.45B$15.74B

Últimas noticias Noticias recientes que mencionan a esta empresa

Señales de trading Señales recientes de compra/venta con precio de entrada y ratio riesgo/recompensa

Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos

📊

Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.

Tu selección se guarda y te sigue en todos los tickers.

Propietarios institucionales (13F) 2 290 declarantes · $77.0B total · A fecha de 30 de junio de 2026

Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.

Actividad institucional — Q2 2026 vs trimestre anterior
Nuevas posiciones Posiciones cerradas Aumentado Disminuido Cambio neto de acciones
319 (+131 vs trimestre anterior) 93 (-97 vs trimestre anterior) 783 (+85 vs trimestre anterior) 714 (-58 vs trimestre anterior) +184.0M

Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.

Institución Valor Acciones % de 13F rastreadas Tipo
VANGUARD CAPITAL MANAGEMENT LLC $8 618 974 924 83 315 369 11,20% Acciones
Capital World Investors $7 753 834 783 74 951 955 10,08% Acciones
STATE STREET CORP $6 236 318 558 60 283 408 8,10% Acciones
Dodge & Cox $5 173 820 539 50 012 765 6,72% Acciones
WELLINGTON MANAGEMENT GROUP LLP $3 266 370 439 31 574 388 4,24% Acciones
VANGUARD PORTFOLIO MANAGEMENT LLC $2 755 624 444 26 637 259 3,58% Acciones
GEODE CAPITAL MANAGEMENT, LLC $2 646 473 316 25 714 722 3,44% Acciones
Capital Research Global Investors $2 516 851 376 24 329 151 3,27% Acciones
NORGES BANK $1 866 126 481 18 038 922 2,42% Acciones
FMR LLC $1 684 924 609 16 287 333 2,19% Acciones
Capital International Investors $1 591 868 430 15 387 600 2,07% Acciones
Davis Selected Advisers $1 227 594 458 11 865 916 1,60% Acciones
Clearbridge Investments, LLC $878 119 687 8 488 349 1,14% Acciones
GQG Partners LLC $822 989 370 7 955 411 1,07% Acciones
AMERIPRISE FINANCIAL INC $761 355 564 7 357 966 0,99% Acciones
VANGUARD FIDUCIARY TRUST CO $741 242 940 7 165 229 0,96% Acciones
DIMENSIONAL FUND ADVISORS LP $643 180 166 6 217 304 0,84% Acciones
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $524 415 257 5 069 263 0,68% Acciones
GLENVIEW CAPITAL MANAGEMENT, LLC $499 125 457 4 824 799 0,65% Acciones
CITADEL ADVISORS LLC $493 765 609 4 772 988 0,64% Acciones
VIKING GLOBAL INVESTORS LP $378 974 695 3 663 361 0,49% Acciones
Swiss National Bank $371 195 152 3 588 160 0,48% Acciones
BlackRock, Inc. $364 982 048 3 528 101 0,47% Acciones
RAYMOND JAMES FINANCIAL INC $354 997 941 3 431 590 0,46% Acciones
National Pension Service $352 166 145 3 404 216 0,46% Acciones
ROYAL BANK OF CANADA $338 495 000 3 272 060 0,44% Acciones
Mitsubishi UFJ Asset Management Co., Ltd. $322 653 390 3 118 927 0,42% Acciones
GOLDMAN SACHS GROUP INC $319 964 422 3 092 938 0,42% Acciones
Legal & General Group Plc $315 302 980 3 047 878 0,41% Acciones
Holocene Advisors, LP $310 524 210 3 001 684 0,40% Acciones
ENVESTNET ASSET MANAGEMENT INC $300 309 006 2 902 944 0,39% Acciones
CITADEL ADVISORS LLC $299 591 200 2 896 000 0,39% Opción de compra
Sumitomo Mitsui Trust Group, Inc. $298 855 050 2 888 884 0,39% Acciones
Vanguard Global Advisers, LLC $295 578 375 2 857 210 0,38% Acciones
VANGUARD ASSET MANAGEMENT, Ltd $295 497 373 2 856 427 0,38% Acciones
FAIRFAX FINANCIAL HOLDINGS LTD/ CAN $280 502 160 2 712 000 0,36% Acciones
CITADEL ADVISORS LLC $267 076 865 2 581 700 0,35% Opción de venta
BNP PARIBAS FINANCIAL MARKETS $261 748 880 2 530 197 0,34% Acciones
BANK OF AMERICA CORP /DE/ $249 417 276 2 410 993 0,32% Acciones
PRIMECAP MANAGEMENT CO/CA/ $246 778 944 2 385 490 0,32% Acciones
RHUMBLINE ADVISERS $246 744 475 2 385 158 0,32% Acciones
FRANKLIN RESOURCES INC $238 592 528 2 306 356 0,31% Acciones
California Public Employees Retirement System $233 879 967 2 260 802 0,30% Acciones
ALLIANCEBERNSTEIN L.P. $232 194 060 3 233 000 0,30% Acciones
JANE STREET GROUP, LLC $231 055 575 2 233 500 0,30% Opción de venta
CANADA PENSION PLAN INVESTMENT BOARD $230 615 292 2 229 244 0,30% Acciones
Canoe Financial LP $226 952 024 2 193 833 0,29% Acciones
MILLENNIUM MANAGEMENT LLC $223 951 974 2 164 833 0,29% Acciones
VANGUARD GROUP INC $222 935 255 2 809 164 0,29% Acciones
UBS Group AG $221 527 830 2 141 400 0,29% Opción de compra
Brandywine Global Investment Management, LLC $216 103 153 2 723 074 0,28% Acciones
Robeco Institutional Asset Management B.V. $207 806 227 2 008 760 0,27% Acciones
Zurcher Kantonalbank (Zurich Cantonalbank) $205 293 939 1 984 475 0,27% Acciones
Point72 Asset Management, L.P. $202 868 760 1 961 032 0,26% Acciones
JANUS HENDERSON GROUP PLC $200 732 734 2 794 942 0,26% Acciones
JANE STREET GROUP, LLC $190 306 620 1 839 600 0,25% Opción de compra
JONES FINANCIAL COMPANIES LLLP $186 577 346 1 788 167 0,24% Acciones
Assenagon Asset Management S.A. $183 757 718 1 776 295 0,24% Acciones
MACKENZIE FINANCIAL CORP $177 786 480 1 718 574 0,23% Acciones
Hamlin Capital Management, LLC $177 686 548 1 717 608 0,23% Acciones
Alyeska Investment Group, L.P. $174 358 768 1 685 440 0,23% Acciones
ADAGE CAPITAL PARTNERS GP, L.L.C. $169 576 171 1 639 209 0,22% Acciones
LPL Financial LLC $160 912 185 1 555 458 0,21% Acciones
PRUDENTIAL FINANCIAL INC $156 319 985 1 511 068 0,20% Acciones
GOLDMAN SACHS GROUP INC $153 033 585 1 479 300 0,20% Opción de compra
Quantinno Capital Management LP $150 197 267 1 451 882 0,20% Acciones
PRINCIPAL FINANCIAL GROUP INC $149 812 359 1 448 162 0,19% Acciones
NEW YORK STATE COMMON RETIREMENT FUND $146 277 266 1 413 990 0,19% Acciones
VICTORY CAPITAL MANAGEMENT INC $143 800 879 1 390 052 0,19% Acciones
PANAGORA ASSET MANAGEMENT INC $143 310 113 1 385 308 0,19% Acciones
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $135 669 704 1 889 024 0,18% Acciones
MANUFACTURERS LIFE INSURANCE COMPANY, THE $133 185 771 1 287 441 0,17% Acciones
BARCLAYS PLC $130 962 631 1 265 951 0,17% Acciones
UBS Group AG $130 742 593 1 263 824 0,17% Acciones
MACQUARIE GROUP LTD $130 222 860 1 258 800 0,17% Acciones
Patient Capital Management, LLC $127 813 106 1 235 505 0,17% Acciones
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. $125 407 000 1 212 248 0,16% Acciones
Maple Rock Capital Partners Inc. $123 932 686 1 197 996 0,16% Acciones
BANK OF MONTREAL /CAN/ $120 915 774 1 168 833 0,16% Acciones
Qube Research & Technologies Ltd $118 745 083 1 147 850 0,15% Acciones
TD Asset Management Inc $117 174 298 1 132 666 0,15% Acciones
SCHRODER INVESTMENT MANAGEMENT GROUP $114 781 970 1 108 148 0,15% Acciones
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND $114 360 975 1 105 471 0,15% Acciones
AVIVA PLC $113 872 588 1 100 750 0,15% Acciones
Integral Health Asset Management, LLC $113 795 000 1 100 000 0,15% Acciones
LETKO, BROSSEAU & ASSOCIATES INC $113 305 164 1 095 265 0,15% Acciones
TRUIST FINANCIAL CORP $112 799 640 1 090 378 0,15% Acciones
Woodline Partners LP $112 125 214 1 083 859 0,15% Acciones
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM $111 580 653 1 078 595 0,14% Acciones
STOREBRAND ASSET MANAGEMENT AS $111 494 582 1 077 763 0,14% Acciones
NORDEA INVESTMENT MANAGEMENT AB $110 986 994 1 076 081 0,14% Acciones
BANK OF NOVA SCOTIA $103 790 874 1 003 295 0,13% Acciones
Capital International, Inc./CA/ $102 952 716 995 193 0,13% Acciones
Universal- Beteiligungs- und Servicegesellschaft mbH $100 146 711 970 080 0,13% Acciones
Walleye Trading LLC $98 691 300 954 000 0,13% Opción de compra
Walleye Trading LLC $98 049 910 947 800 0,13% Opción de venta
Korea Investment CORP $97 590 385 943 358 0,13% Acciones
JENNISON ASSOCIATES LLC $97 539 798 942 869 0,13% Acciones
SEB Asset Management AB $96 760 081 935 333 0,13% Acciones
WORLDQUANT MILLENNIUM ADVISORS LLC $91 910 670 888 455 0,12% Acciones

Informantes de la empresa 86 insiders · 48 directivos · 41 consejeros

Insider Rol Última actividad Acciones en propiedad Compras 12m Ventas 12m Neto 12m
David J. Joyner President, CEO and Chair 1 de abril de 2026 F 70 349 0 0 $0
Karen S Lynch President and CEO 1 de abril de 2024 A 74 687 0 0 $0
Brian Newman EVP, Chief Financial Officer 31 de mayo de 2026 F 3 008 0 0 $0
Thomas F. Cowhey EVP and CFO 1 de abril de 2025 A 41 109 0 0 $0
Shawn M Guertin EVP & Chief Financial Officer 1 de abril de 2023 A 34 706 0 0 $0
Eva C Boratto EVP & CFO 4 de mayo de 2021 S 115 331 0 0 $0
David M Denton EVP and CFO 29 de noviembre de 2018 S 403 0 0 $0
David B Rickard Chief Financial Officer 14 de diciembre de 2009 M 207 179 0 0 $0
Howard A Mclure President, Caremark Pharm Serv 2 de noviembre de 2009 M 0 0 0 $0
Jonathan C Roberts EVP & Chief Operating Officer 1 de abril de 2022 A 426 025 0 0 $0
James David Clark SVP, Cont & Chief Acct Officer 26 de junio de 2026 F 27 606 0 0 $0
Amy Compton-Phillips EVP, Chief Medical Officer 31 de mayo de 2026 F 9 557 0 0 $0
Tilak Mandadi EVP, Chief Exp & Tech Officer 8 de mayo de 2026 S 10 133 0 1 $-6 230 379
Prem S Shah EVP and Group President 31 de marzo de 2026 A 64 356 0 0 $0
Heidi B Capozzi EVP and Chief People Officer 31 de marzo de 2026 A 13 023 3 0 $4 588
Samrat S. Khichi EVP, CPO and General Counsel 31 de marzo de 2026 A 33 421 0 0 $0
Steven H Nelson EVP and President, Aetna 31 de marzo de 2026 A 2 900 1 0 $1 289
Sreekanth K Chaguturu EVP and Chief Medical Officer 1 de abril de 2024 A 23 666 0 0 $0
Laurie P. Havanec EVP and Chief People Officer 1 de abril de 2024 A 9 426 0 0 $0
Brian A Kane EVP/President, Aetna 1 de abril de 2024 A 12 569 0 0 $0
Finke Daniel P EVP/Pres, Health Care Benefits 1 de abril de 2023 A 35 068 0 0 $0
Michelle A Peluso EVP and Co-President of Retail 1 de abril de 2023 A 124 383 0 0 $0
Thomas M Moriarty EVP & General Counsel 31 de diciembre de 2022 F 315 273 0 0 $0
Alan Lotvin EVP&President-PharmacyServices 4 de agosto de 2022 M 109 183 0 0 $0
Troyen A Brennan EVP and Chief Medical Officer 3 de abril de 2022 F 232 676 0 0 $0
Neela Montgomery EVP and Pres., Pharmacy/Retail 1 de abril de 2021 A 29 502 0 0 $0
Lisa Bisaccia Former EVP & Chief HR Officer 1 de abril de 2021 F 66 417 0 0 $0
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL 28 de febrero de 2021 F 25 657 0 0 $0
Jonathan E. Mayhew EVP - Transformation 2 de diciembre de 2020 F 6 855 0 0 $0
Derica W Rice EVP & President, CVS Caremark 28 de febrero de 2020 F 26 827 0 0 $0
Kevin Hourican EVP & President, CVS Pharmacy 1 de abril de 2019 A 15 237 0 0 $0
Helena Foulkes EVP & President-CVS Pharmacy 16 de febrero de 2018 M 45 107 0 0 $0
Robert O. Kraft EVP and President - Omnicare 3 de abril de 2017 A 92 360 0 0 $0
Andrew Sussman EVP, Clinical Services 3 de abril de 2017 A 16 433 0 0 $0
Stephen J Gold EVP & CIO 3 de abril de 2017 A 46 818 0 0 $0
Per Gh Lofberg EVP 2 de enero de 2015 M 23 419 0 0 $0
Mark Cosby EVP & President-CVS/pharmacy 30 de septiembre de 2013 M 45 955 0 0 $0
Laird Daniels SVP, Cont & Chief Acct Officer 1 de abril de 2013 A 17 845 0 0 $0
Douglas A Sgarro EVP and CLO 11 de mayo de 2012 M 214 0 0 $0
Stuart M Mcguigan SVP and CIO 16 de marzo de 2012 M 10 967 0 0 $0
Thomas M Ryan Non-Executive Chairman 3 de abril de 2011 F 1 156 702 0 0 $0
Sara Finley SVP, Gen Counsel 18 de febrero de 2011 F 29 053 0 0 $0
Michael V Ferdinandi Senior Vice President 19 de agosto de 2009 S 16 021 0 0 $0
Paula A Price Controller 12 de febrero de 2008 A 16 498 0 0 $0
Edwin M Crawford Chairman 29 de octubre de 2007 A 135 572 0 0 $0
William R Spalding EVP Caremark Pharmacy Services 18 de junio de 2007 M 182 0 0 $0
Gregory S Weishar Vice President 3 de abril de 2006 A 30 161 0 0 $0
Larry D Solberg Senior Vice President 16 de febrero de 2006 A 5 978 0 0 $0
ROBBINS LARRY Consejero 21 de mayo de 2026 S 4 824 799 0 8 $-352 750 556
Fernando Aguirre Consejero 21 de mayo de 2026 D 10 513 0 0 $0

Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto

Activistas y propietarios del %+ 5 1 tenencia

Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.

Declarante Presentado Participación Estado Propósito Presentación
CVS Caremark Corporation 7 de enero de 2011 Presentación inicial M&A / venta SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Propiedad de ETFs Mantenido por 218 ETFs

El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.

Fondo Ponderación Unidades A fecha de Fuente
IHF · iShares Trust 13,66% 1 756 753 SH 8 de agosto de 2026 Diario
ROPE · EA Series Trust 5,27% 4 922 NS 29 de mayo de 2026 N-PORT
DUSA · Davis Fundamental ETF Trust 4,57% 636 042 NS 30 de abril de 2026 N-PORT
IYK · iShares Trust 4,22% 624 816 SH 8 de agosto de 2026 Diario
GEND · Spinnaker ETF Series 3,66% 1 968 NS 30 de abril de 2026 N-PORT
PEZ · Invesco Exchange-Traded Fund Trust 3,42% 8 210 SH 8 de agosto de 2026 Diario
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 2,71% 3 618 NS 30 de abril de 2026 N-PORT
ESN · Northern Lights Fund Trust II 2,58% 79 142 NS 31 de mayo de 2026 N-PORT
DWLD · Davis Fundamental ETF Trust 2,33% 158 312 NS 30 de abril de 2026 N-PORT
SDOG · ALPS ETF Trust 2,25% 342 879 NS 31 de mayo de 2026 N-PORT
COWZ · Pacer Funds Trust 2,16% 4 706 232 NS 30 de abril de 2026 N-PORT
QQWZ · Pacer Funds Trust 2,15% 12 078 NS 30 de abril de 2026 N-PORT
RWL · Invesco Exchange-Traded Fund Trust … 1,95% 2 024 890 SH 8 de agosto de 2026 Diario
VHT · VANGUARD WORLD FUND 1,94% 3 824 297 SH 8 de agosto de 2026 Diario
FXG · First Trust Exchange-Traded AlphaDE… 1,89% 55 579 NS 30 de abril de 2026 N-PORT
RPV · Invesco Exchange-Traded Fund Trust 1,88% 334 242 SH 8 de agosto de 2026 Diario
SPDV · ETF Series Solutions 1,86% 20 100 NS 30 de abril de 2026 N-PORT
FHLC · FIDELITY COVINGTON TRUST 1,71% 585 200 NS 30 de abril de 2026 N-PORT
RXL · ProShares Trust 1,67% 13 266 NS 31 de mayo de 2026 N-PORT
IXJ · iShares Trust 1,55% 670 400 SH 8 de agosto de 2026 Diario
REVS · Columbia ETF Trust I 1,55% 52 621 NS 30 de abril de 2026 N-PORT
CURE · Direxion Shares ETF Trust 1,53% 25 368 NS 30 de abril de 2026 N-PORT
RSPH · Invesco Exchange-Traded Fund Trust 1,48% 120 955 SH 8 de agosto de 2026 Diario
SPVM · Invesco Exchange-Traded Fund Trust 1,45% 19 889 SH 8 de agosto de 2026 Diario
PWV · Invesco Exchange-Traded Fund Trust 1,40% 261 212 SH 8 de agosto de 2026 Diario
VLUE · iShares Trust 1,38% 1 353 743 SH 8 de agosto de 2026 Diario
DVY · iShares Trust 1,37% 3 341 969 SH 8 de agosto de 2026 Diario
ITAN · EA Series Trust 1,36% 13 295 NS 29 de mayo de 2026 N-PORT
GKAT · Advisors Series Trust 1,30% 27 039 NS 31 de marzo de 2026 N-PORT
GMOV · GMO ETF Trust 1,21% 12 118 NS 31 de mayo de 2026 N-PORT
BSCS · Invesco Exchange-Traded Self-Indexe… 1,17% 41 394 000 8 de agosto de 2026 Diario
GURU · Global X Funds 1,17% 8 187 NS 30 de abril de 2026 N-PORT
SPVU · Invesco Exchange-Traded Fund Trust … 1,13% 16 706 NS 31 de mayo de 2026 N-PORT
SPXD · DBX ETF Trust 1,12% 830 NS 31 de mayo de 2026 N-PORT
VRP · Invesco Exchange-Traded Fund Trust … 1,11% 31 567 000 8 de agosto de 2026 Diario
CVAR · ETF Opportunities Trust 1,01% 4 716 NS 30 de abril de 2026 N-PORT
VCEB · VANGUARD WORLD FUND 0,99% 12 250 700 PA 8 de agosto de 2026 Diario
CGCV · Capital Group Conservative Equity E… 0,99% 189 872 NS 31 de mayo de 2026 N-PORT
PALC · Pacer Funds Trust 0,98% 27 132 NS 30 de abril de 2026 N-PORT
ABCS · EA Series Trust 0,98% 1 219 NS 29 de mayo de 2026 N-PORT
FFLV · FIDELITY COVINGTON TRUST 0,97% 2 025 NS 30 de abril de 2026 N-PORT
VFVA · VANGUARD WELLINGTON FUND 0,95% 77 895 SH 8 de agosto de 2026 Diario
EQWL · Invesco Exchange-Traded Fund Trust 0,92% 267 202 SH 8 de agosto de 2026 Diario
FNDX · SCHWAB STRATEGIC TRUST 0,91% 2 553 383 NS 31 de mayo de 2026 N-PORT
VCLT · VANGUARD SCOTTSDALE FUNDS 0,91% 98 192 000 PA 8 de agosto de 2026 Diario
IUS · Invesco Exchange-Traded Self-Indexe… 0,88% 87 427 SH 8 de agosto de 2026 Diario
AKAF · ETF Series Solutions 0,84% 271 NS 31 de mayo de 2026 N-PORT
FNDB · SCHWAB STRATEGIC TRUST 0,83% 120 850 NS 31 de mayo de 2026 N-PORT
RECS · Columbia ETF Trust I 0,81% 529 096 NS 30 de abril de 2026 N-PORT
FEUS · FlexShares Trust 0,81% 10 773 NS 30 de abril de 2026 N-PORT